<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作為您在 Google 上的首選新聞來源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>Alpha Tau Medical Ltd.（DRTS）的股價在週一的盤前交易中上漲超過 12%，達到 9.60 美元，此次上漲是由於其美國 Alpha DaRT 複發性膠質母細胞瘤試驗 REGAIN 的中期結果令人鼓舞。</p>
<p>REGAIN 研究是一項前瞻性、開放標籤、單臂干預研究，旨在評估 Alpha DaRT 在複發性膠質母細胞瘤潛在治療中的可行性和安全性，這是一種最常見且最具侵襲性的腦癌。</p>
<p>Alpha DaRT（擴散α放射治療）旨在將鐳-224 直接輸送到腫瘤中，以釋放強烈的局部α輻射，精確靶向並摧毀實體癌細胞。</p>
<p>根據國家腦腫瘤協會的數據，膠質母細胞瘤是最複雜、最致命且對治療抵抗力最強的癌症之一，估計平均生存率僅為 8 個月。</p>
<p>REGAIN 研究旨在招募 10 名腦癌患者，今天報告的中期結果來自首批接受治療的三名患者。</p>
<p>根據試驗結果，三名接受治療的患者中有兩名顯示出完全反應，所有增強腫瘤病灶在多次治療後 MRI 掃描中完全消失。</p>
<p>Alpha Tau 的首席醫療官 Robert Den 對研究結果評論道：“看到我們複發性膠質母細胞瘤方案的這些中期結果令人非常欣慰。在這種復發後中位生存期通常低於 12 個月的疾病中，令人鼓舞的方法屢次未能轉化為成功結果，這種活性和耐受性的特徵為我們推進試驗至完全招募提供了強有力的依據。”</p>
<p>當我們在 2025 年 12 月 11 日提醒讀者關注 DRTS 時，股價為 5 美元。該股票在 2026 年 5 月 8 日（週五）的收盤價為 8.51 美元，上漲 8.41%。</p>
<p>如有意見和反饋，請聯繫：editorial@rttnews.com</p>
<p>商業新聞</p>

DRTS

<p>Alpha Tau Medical Ltd.（DRTS）的股票在盤前交易中上漲超過 12%，達到 9.60 美元，此前其針對複發性膠質母細胞瘤的 REGAIN 試驗發佈了積極的中期結果。該研究旨在評估 Alpha DaRT 治療的安全性和可行性，結果顯示三名患者中有兩名完全緩解，未見腫瘤病灶。首席醫學官羅伯特·登（Robert Den）對結果表示樂觀，強調了推進試驗的潛力</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作為您在 Google 上的首選新聞來源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Shares of Alpha Tau Medical Ltd. (DRTS) are up over 12% at $9.60 in premarket trading on Monday, following encouraging interim results from its U.S. Alpha DaRT recurrent glioblastoma trial, dubbed REGAIN.</p>
<div class="lb-trans"><p>Alpha Tau Medical Ltd.（DRTS）的股價在週一的盤前交易中上漲超過 12%，達到 9.60 美元，此次上漲是由於其美國 Alpha DaRT 複發性膠質母細胞瘤試驗 REGAIN 的中期結果令人鼓舞。</p>
</div><p>The REGAIN study is a prospective, open-label, single-arm interventional study designed to evaluate the feasibility and safety of Alpha DaRT for the potential treatment of recurrent glioblastoma, the most common and aggressive form of brain cancer.</p>
<div class="lb-trans"><p>REGAIN 研究是一項前瞻性、開放標籤、單臂干預研究，旨在評估 Alpha DaRT 在複發性膠質母細胞瘤潛在治療中的可行性和安全性，這是一種最常見且最具侵襲性的腦癌。</p>
</div><p>Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to deliver radium-224 directly into tumors to release strong, localized alpha radiation that precisely targets and destroys solid cancer cells.</p>
<div class="lb-trans"><p>Alpha DaRT（擴散α放射治療）旨在將鐳-224 直接輸送到腫瘤中，以釋放強烈的局部α輻射，精確靶向並摧毀實體癌細胞。</p>
</div><p>Glioblastoma is one of the most complex, deadly, and treatment-resistant cancers, with an estimated average survival rate of only 8 months, according to the National Brain Tumor Society.</p>
<div class="lb-trans"><p>根據國家腦腫瘤協會的數據，膠質母細胞瘤是最複雜、最致命且對治療抵抗力最強的癌症之一，估計平均生存率僅為 8 個月。</p>
</div><p>The REGAIN study is designed to enroll 10 brain cancer patients and the interim results reported today were from the first three treated patients.</p>
<div class="lb-trans"><p>REGAIN 研究旨在招募 10 名腦癌患者，今天報告的中期結果來自首批接受治療的三名患者。</p>
</div><p>According to the trial results, two of the three treated patients showed a complete response, with total disappearance of all enhancing tumor lesions on multiple post-treatment MRI scans.</p>
<div class="lb-trans"><p>根據試驗結果，三名接受治療的患者中有兩名顯示出完全反應，所有增強腫瘤病灶在多次治療後 MRI 掃描中完全消失。</p>
</div><p>Commenting on the study results, Robert Den, Chief Medical Officer of Alpha Tau, said, &#34;It is immensely gratifying to see these interim results of our recurrent glioblastoma protocol. In a disease where median survival after recurrence is typically under 12 months and where promising approaches have repeatedly failed to translate to successful outcomes, this profile of activity and tolerability gives us strong rationale to advance the trial toward full accrual.&#34;</p>
<div class="lb-trans"><p>Alpha Tau 的首席醫療官 Robert Den 對研究結果評論道：“看到我們複發性膠質母細胞瘤方案的這些中期結果令人非常欣慰。在這種復發後中位生存期通常低於 12 個月的疾病中，令人鼓舞的方法屢次未能轉化為成功結果，這種活性和耐受性的特徵為我們推進試驗至完全招募提供了強有力的依據。”</p>
</div><p>When we alerted readers to DRTS on December 11, 2025, it was at $5. The stock closed Friday's (May 8, 2026) trading at $8.51, up 8.41%.</p>
<div class="lb-trans"><p>當我們在 2025 年 12 月 11 日提醒讀者關注 DRTS 時，股價為 5 美元。該股票在 2026 年 5 月 8 日（週五）的收盤價為 8.51 美元，上漲 8.41%。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意見和反饋，請聯繫：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商業新聞</p>
</div>

Alpha Tau 在腦癌研究數據上重新獲得了發展勢頭